



Review Article



AGO Breast Committee recommendations for the surgical therapy of breast cancer: Working Group on Gynecologic Cancers (AGO) update 2026[☆]

Maggie Banys-Paluchowski^{a,b,1,*}, Christine Solbach^{c,1}, Thorsten Kühn^{d,e,1}, Volkmar Müller^f, Nina Ditsch^g, Tanja Fehm^h, Ute-Susann Albertⁱ, Rupert Bartsch^j, Ingo Bauerfeind^k, Jens-Uwe Blohmer^l, Wilfried Budach^m, Peter Dallⁿ, Eva Maria Fallenberg^o, Peter A. Fasching^p, Michael Friedrich^q, Oleg Gluz^r, Nadia Harbeck^s, Andreas Hartkopf^t, Jörg Heil^u, Juliane Hörner-Rieber^m, Jens Huober^v, Wolfgang Janni^e, Hans-Heinrich Kreipe^w, David Krug^x, Sherko Kümmel^y, Sibylle Loibl^z, Diana Lüftner^{aa}, Michael Patrick Lux^{ab}, Nicolai Maass^{ac}, Marion Tina van Mackelenbergh^{ac}, Christoph Mundhenke^{ad}, Tjong-Won Park-Simon^{ae}, Mattea Reinisch^{af}, Kerstin Rhiem^{ag}, Achim Rody^{a,b}, Marcus Schmidt^{ah}, Andreas Schneeweiss^{ai}, Florian Schütz^{aj}, Hans-Peter Sinn^{ak}, Erich-Franz Solomayer^{al}, Elmar Stickeler^{am}, Michael Untch^{an}, Isabell Witzel^{ao}, Achim Wöckelⁱ, Rachel Wuerstlein^s, Toralf Reimer^{ap,1}, Vesna Bjelic-Radicic^{aq,1}, Marc Thill^{ar,1}

^a Department of Gynecology and Obstetrics, University of Luebeck, Lübeck, Germany

^b Department of Gynecology and Obstetrics, University Hospital Schleswig-Holstein Campus Lübeck, Lübeck, Germany

^c Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Frankfurt, Frankfurt, Germany

^d Die Filderklinik, Filderstadt, Germany

^e Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Ulm, Ulm, Germany

^f Klinik und Poliklinik für Gynäkologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany

^g Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Augsburg, Augsburg, Germany

^h Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum Düsseldorf, Düsseldorf, Germany

ⁱ Klinik für Frauenheilkunde und Geburtshilfe, Universitätsklinikum Würzburg, Würzburg, Germany

^j Klinik für Innere Medizin I, Abteilung für klinische Onkologie, Medizinische Universität Wien, Austria

^k Frauenklinik und Brustkrebszentrum LA-Regio-Kliniken, Klinikum Landshut Mitte, Landshut, Germany

^l Klinik für Gynäkologie mit Brustzentrum, Charité-Universitätsmedizin Berlin, Berlin, Germany

^m Klinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Düsseldorf, Düsseldorf, Germany

ⁿ Frauenklinik, Städtisches Klinikum Lüneburg, Lüneburg, Germany

^o TUM Klinikum Rechts der Isar, Klinik und Poliklinik für Frauenheilkunde, Munich, Germany

^p Universitätsfrauenklinik, Universitätsklinikum Erlangen, Erlangen, Germany

^q Klinik für Frauenheilkunde und Geburtshilfe, Helios Klinikum Krefeld, Krefeld, Germany

^r Brustzentrum, Evang. Krankenhaus Bethesda, Mönchengladbach, Germany

^s Breast Center, Department of Gynecology and Obstetrics, LMU University Hospital Munich and CCC Munich, Munich, Germany

^t Department für Frauengesundheit, Universitätsfrauenklinik, Tübingen, Germany

^u Brustzentrum Heidelberg, Klinik St. Elisabeth, and Medizinische Fakultät der Ruprecht-Karls-Universität Heidelberg, Universitätsklinikum Heidelberg, Abteilung für Gynäkologie und Geburtshilfe, Heidelberg, Germany

^v Brustzentrum, HOCH Health Ostschweiz, Kantonsspital St. Gallen, St. Gallen, Switzerland

^w Institut für Pathologie, Medizinische Hochschule Hannover, Hannover, Germany

^x Klinik für Strahlentherapie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany

^y Klinik für Senologie, Evangelische Kliniken Essen Mitte, Essen, Germany

^z German Breast Group Forschungs GmbH, Frankfurt, Germany

^{aa} Fachklinik für Onkologische Rehabilitation, Immanuel Hospital Märkische Schweiz, Buckow and Immanuel Hospital Rüdersdorf / Medical University of Brandenburg Theodor Fontane, Rüdersdorf, Germany

[☆] A member of the Editorial Board is an author of this article. Editorial Board members are not involved in decisions about papers which they have written themselves or have been written by family members or colleagues or which relate to products or services in which the editor has an interest. Any such submission is subject to all of the journal's usual procedures, with peer review handled independently of the relevant editor and their research groups.

* Corresponding author. Department of Gynecology and Obstetrics, University of Luebeck, Lübeck, Germany.

E-mail address: Maggie.Banys-Paluchowski@uksh.de (M. Banys-Paluchowski).

^{ab} Klinik für Gynäkologie und Geburtshilfe, St. Vincenz Kliniken Salzkotten & Paderborn, Germany
^{ac} Klinik für Gynäkologie und Geburtshilfe, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany
^{ad} OB/GYN, Klinikum Bayreuth and Friedrich-Alexander-Universität Erlangen/Medical Campus Upper Franconia (MCO) Bayreuth, Germany
^{ae} Klinik für Frauenheilkunde und Geburtshilfe, Medizinische Hochschule Hannover, Hannover, Germany
^{af} Frauenklinik, Universitätsklinikum Mannheim, Mannheim, Germany
^{ag} Zentrum Familiärer Brust- und Eierstockkrebs, Universitätsklinikum Köln, Köln, Germany
^{ah} Klinik und Poliklinik für Geburtshilfe und Frauengesundheit der Johannes-Gutenberg-Universität Mainz, Mainz, Germany
^{ai} Nationales Centrum für Tumorerkrankungen, Universitätsklinikum und Deutsches Krebsforschungszentrum, Heidelberg, Germany
^{aj} Klinik für Gynäkologie und Geburtshilfe, Diakonissen Krankenhaus Speyer, Speyer, Germany
^{ak} Sektion Gynäcopathologie, Pathologisches Institut, Universitätsklinikum Heidelberg, Heidelberg, Germany
^{al} Klinik für Frauenheilkunde, Geburtshilfe und Reproduktionsmedizin, Universitätsklinikum des Saarlandes, Homburg, Germany
^{am} Klinik für Gynäkologie und Geburtsmedizin, Universitätsklinikum Aachen und CIO ABCD, Aachen, Germany
^{an} Klinik für Gynäkologie und Geburtshilfe, Helios Klinikum Berlin-Buch, Berlin, Germany
^{ao} Klinik für Gynäkologie, Universitätsspital Zürich, Universität Zürich, Zürich, Switzerland
^{ap} Universitätsfrauenklinik und Poliklinik am Klinikum Südstadt, Rostock, Germany
^{aq} Brustzentrum und Abteilung Senologie, Helios Universitätsklinikum Wuppertal, Germany
^{ar} Klinik für Gynäkologie und Gynäkologische Onkologie, Agaplesion Markus Krankenhaus, Frankfurt, Germany

ARTICLE INFO

Keywords:
Breast cancer
Breast surgery
Targeted axillary dissection
Sentinel lymph node biopsy
Breast lesion localization
Guidelines

ABSTRACT

The German Guideline Committee (AGO: Working Group on Gynecologic Cancers) updated its yearly recommendations on the diagnosis and treatment of breast cancer in March 2026. Chapters on oncological and oncoplastic-reconstructive surgery are coordinated with the Working Group for Plastic, Aesthetic, and Reconstructive Surgery in Gynecology (AWOgyn). The most important changes include the omission of sentinel lymph node biopsy (SLNB) and preferred axillary staging in patients with node-positive breast cancer undergoing neoadjuvant chemotherapy (NACT). Targeted axillary dissection (TAD) is endorsed as the method of choice [AGO ++] in patients converting from cN + to ycN0 status, and other de-escalated techniques (SLNB, target lymph node biopsy [TLNB]) are also possible options [AGO +]. Following NACT, ALND is indicated only when macrometastatic disease is detected in the sentinel and/or in the target lymph node.

1. Introduction

Each year, the interdisciplinary AGO Breast Committee issues updated, state-of-the-art recommendations for the prevention, diagnosis, and treatment of breast cancer. These updates follow a structured and documented algorithm [1,2]. The most recent and relevant publications are systematically reviewed, and their scientific validity is assessed using the Oxford Level of Evidence (LoE). The strength of each recommendation is determined according to the Oxford Grades of Recommendation (GR) as well as the AGO grading system (Table 1) [3]. The latest updated recommendations were released by the AGO Breast Committee in March 2026 [4,5]. Two chapters focus on surgical treatment and are consented with the AWOgyn (Working Group for Plastic, Aesthetic and Reconstructive Surgery in Gynecology):

- Breast Cancer Surgery - Oncological Aspects
- Oncoplastic and Reconstructive Breast Surgery

Table 1
AGO grades of recommendation.

AGO ++	This investigation or therapeutic intervention is highly beneficial for patients, can be recommended without restriction, and should be performed
AGO +	This investigation or therapeutic intervention is of limited benefit for patients and can be performed
AGO +/-	This investigation or therapeutic intervention has not shown benefit for patients and may be performed only in individual cases. According to current knowledge a general recommendation cannot be given.
AGO -	This investigation or therapeutic intervention can be of disadvantage for patients and might not be performed
AGO --	This investigation or therapeutic intervention is of clear disadvantage for patients and should be avoided or omitted in any case

The Breast Committee of the German Gynecological Oncology Group (AGO) recommendations are updated yearly and are available in English and German at <https://www.ago-breast.com>. Before the voting, the current evidence is discussed and graded within the Committee. This year, the surgery-related chapter focused on axillary staging techniques in upfront surgery and the neoadjuvant setting. The following manuscript presents an overview of updated recommendations for surgical and oncoplastic-reconstructive therapy of breast cancer.

2. Surgical therapy in the upfront surgery setting

2.1. Surgery of the breast

Surgical therapy of the breast in the upfront setting for early breast cancer consists of two primary options: breast-conserving surgery (BCS) and mastectomy, with or without immediate reconstruction. Both approaches are considered standard, and decades of clinical trials have established that BCS followed by radiation yields equivalent rates of local recurrence compared to a mastectomy, while overall survival is at least equivalent for appropriately selected patients [6,7]. The choice between these options is influenced by tumor size relative to breast size, ability to achieve negative margins, patient preference, genetic risk (e. g., BRCA mutation), as well as contraindications to radiation therapy. BCS is associated with better quality of life, fewer complications, and superior cosmetic outcomes compared to mastectomy [8]. Final treatment decisions should be made through a shared decision-making process with the patient. Surgery is one stage within a multi-step breast cancer treatment plan. Treatment should start within 8 weeks of confirmed diagnosis, and every breast surgeon must possess both diagnostic and oncological expertise (AGO ++) [9]. Before deciding on the surgical treatment of the breast and axilla, a careful assessment of the breast and axilla is necessary. For initial staging in patients with breast cancer, a comprehensive medical history and thorough clinical examination are always required. If there is a high risk of metastases and/or relevant symptoms and/or an indication for (neo-)adjuvant chemotherapy or antibody therapy, additional imaging should be performed.

¹ Contributed equally to this manuscript.

The sequence of individual treatments in terms of timing and scope of surgery, systemic therapy, and radiotherapy should be determined within the framework of a multimodal treatment strategy, according to the stage and tumor biology.

Based on the most recent global registry and clinical trial data, at least two-thirds of patients with early-stage breast cancer worldwide are eligible to undergo BCS. The VENUSCANCER analysis of nearly 276,000 women from 39 countries found that the proportion of women with early, node-negative breast cancer treated with BCS plus radiotherapy ranged from 52.5% to 82.2% in high-income countries, with most European countries reporting rates between 67% and 78% [10].

In the case of BCS, non-palpable breast lesions require a localization device for surgical excision. Wire-guided localization (WGL) has long been considered the standard of care for removing non-palpable breast lesions. Over the past two decades, intraoperative ultrasound (IOUS) and various probe-guided methods have expanded the options for lesion localization [11]. Two network meta-analyses of randomized controlled trials indicated that various localization techniques had similar rates of positive margins, ranging from 15 to 21%. IOUS achieves better margin status and lower re-excision rates than WGL, but is limited to solid lesions visible upon ultrasound and requires substantial surgical and diagnostic expertise (AGO ++) [12–14]. Wire-free, non-radioactive methods—such as magnetic or paramagnetic markers, radar reflectors, and radiofrequency identification tags—show very promising early results but are associated with higher initial device costs. MagSeed™ (Endomag, Cambridge, UK), a paramagnetic marker, licensed for breast and axillary placement, has demonstrated similar re-excision rates and resection ratios but less localization failures compared to the guidewire in the randomized MagTotal study [15–17]. Importantly, the experience of surgeons, radiologists, and surgical coordinators was more favorable with the seed. Nevertheless, it should be noted that MagSeed™ localization can be affected by interference from metal surgical instruments and it is not suitable for MRI-based assessment of response during neoadjuvant chemotherapy. Radioactive seed localization (RSL) is well-validated but its application is limited by radiation safety regulations in many countries. Depending on the studies included, meta-analyses comparing RSL and WGL showed equivalent or lower rates of positive margins and lower reoperation rates [18,19]. The multinational ongoing MELODY (Methods for Localization of Different types of breast lesions) study, initiated by the EUBREAST and iBRA-NET, aims to explore the safety, efficacy, and patient-/clinician-reported outcomes of different localization techniques (NCT05559411, <http://eubreast.org/melody>) [11].

The aim of surgical treatment is to remove the tumor with clear resection margins. In BCS for invasive breast cancer with or without an extensive intraductal component (EIC), the goal is to achieve tumor-free margins, with “no ink on tumor” considered an adequate margin—even in cases of unfavorable tumor biology (AGO ++). Re-excision is indicated if invasive or non-invasive tumor cells are found at the margin in the final histology. It should be noted that EIC is not uniformly defined in the literature; according to the German S3 guideline, an increased risk of local recurrence is assumed if the intraductal component is at least twice as large as the largest dimension of the invasive tumor component. Furthermore, in cases of EIC, a second excision should not be performed if the margin of the intraductal component is narrow (<2 mm in the final histology). In this situation, treatment should be tailored to the individual patient, taking into account the patient's age and tumor extent.

IOUS examination increases the negative margin rates in non-palpable and palpable lesions (AGO +). Another advantage of IOUS is that less healthy breast tissue needs to be removed. The COBALT study demonstrated that IOUS resulted in smaller excision volumes than those in palpation-guided surgery, leading to better cosmetic results and higher patient satisfaction [20]. Placement of surgical clips at the margins of the lumpectomy cavity improves the precision and consistency of target volume delineation in both boost and partial breast irradiation settings (AGO +).

In cases of non-palpable lesions and/or tumor-associated microcalcifications, intraoperative radiography and/or ultrasound checks of the specimen should be performed to verify and document complete removal (AGO ++). A systematic review and meta-analysis comparing radiography, digital breast tomosynthesis (DBT), micro-CT, and ultrasound for intraoperative breast margin assessment found that ultrasound had the best and radiography the worst diagnostic performance. Pooled sensitivity, specificity, and AUC were 52%, 77%, and 0.60 for radiography; 67%, 76%, and 0.76 for DBT; 68%, 69%, and 0.72 for micro-CT; and 72%, 78%, and 0.80 for ultrasound [21].

Mastectomy is still recommended for early-stage breast cancer when BCS is contraindicated, not feasible, or not preferred by the patient. Reasons can be inability to obtain negative margins after repeated excisions, extensive, or multicentric disease, diffuse suspicious microcalcifications, contraindications to radiation therapy or limited access to radiotherapy. Individuals with genetic mutations that pose a high risk may opt for a mastectomy to reduce their risk. Skin and nipple sparing mastectomies are considered oncologically safe in appropriately selected patients and improve cosmetic and quality-of-life outcomes compared to traditional mastectomy [22].

2.2. Surgery of the axilla

2.2.1. Axillary surgery for clinically node-negative (cN0) breast cancer

At the beginning of the 21st century, ALND was replaced by SLNB for patients with clinically negative axillary lymph node status [23]. The advantage of SLNB is lower arm morbidity compared to ALND (lymphedema 5–7% versus 10–20%, neuropathy 11% versus 31%, deterioration in quality of life 23% versus 35%) [24]. Despite a false-negative rate (FNR) of 5–8% for SLNB, randomized clinical trials have shown no impact on disease-free or overall survival compared with ALND [3]. SLNB is not recommended in cases of inflammatory breast cancer (AGO -). The standard for marking the sentinel lymph node remains radio-tracer localization with technetium and probe-assisted detection (AGO ++). Alternatively, intraoperative marking with indocyanine green (ICG) and detection with a near-infrared camera or with superparamagnetic iron oxide (SPIO), are increasingly used (AGO +) [25]. ICG is approved for SLN detection in breast cancer in many countries; the most recent regulatory approval was issued in November 2025 in Germany. Due to persisting artifacts potentially masking the tumor bed after BCS, the importance of postoperative surveillance MRI needs to be taken into account when using SPIO. Recently, a prospective cohort study showed that a targeted peritumoral SPIO injection followed by removal of SPIO during BCS may reduce the risk of postoperative MRI artifacts [26].

After the results of the ACOSOG Z0011 study showed no advantage of completion ALND in terms of locoregional recurrence rate and overall survival in patients with 1–2 metastatic sentinel lymph nodes (SLN) [27–30], it is no longer recommended for patients with upfront BCS, tumor stages T1–T3, postoperative whole-breast irradiation, and an adequate systemic therapy (AGO -). The analyses of Z0011 validation studies (SINODAR-ONE, SENOMAC) have confirmed the non-inferiority of the SLNB-alone arm compared to completion ALND. However, the median published follow-up in both trials is still below 5 years [31,32]. In the SENOMAC study, the inclusion criteria were extended to T3 carcinomas. Only the secondary outcome analysis of the second randomisation within the INSEMA study failed to fully confirm the non-inferiority of the SLNB-only arm in patients with 1–3 sentinel macrometastases and BCS, with a median follow-up of 6.2 years [33]. The pending analyses of the primary objectives of the two largest Z0011 validation studies, SENOMAC (5-year overall survival) and POSNOC (axillary recurrence rate after 5 years), are therefore awaited [34,35]. In the context of ALND omission in patients with sentinel lymph node macrometastases, inclusion of axillary levels I–IV (AGO +) according to the AMAROS and OTOASOR trials or of axillary levels I/II up to 5 mm below the axillary vein in analogy to the Z0011 trial (AGO +; only when

there is no indication for regional nodal irradiation (RNI) based on other risk factors) is recommended.

For patients undergoing primary mastectomy, the recommendation regarding completion ALND in cases of 1-2 sentinel macrometastases depends on whether a post-mastectomy radiotherapy (PMRT) is planned or not. In 2024, secondary outcome data from the prospective randomised SENOMAC study (with more than one third of patients undergoing mastectomy [n = 920]) were published. After a median follow-up of 46.8 months, no difference in recurrence-free survival was observed in the mastectomy subgroup with a maximum of 2 metastatic SLNs and no ALND (91.6% versus 89.5%) [32]. However, the de-escalation of axillary surgery was partially offset by an escalation of postoperative radiotherapy. Almost all SENOMAC patients received PMRT as well as regional nodal irradiation (RNI) to the ipsilateral lymph drainage areas (axillary levels II-IV, interpectoral) [36].

Currently, completion ALND in case of 1-2 sentinel macrometastases following a mastectomy can be omitted only in cases of PMRT with RNI (AGO -) [37]. If there is no indication for PMRT, completion ALND should only be omitted in individual cases (AGO +/-). In the randomized-controlled SUPREMO trial which showed no benefit of PMRT in patients with intermediate risk-breast cancer, all patients with node-positive disease underwent ALND [38]. Only a small subgroup of the SINODAR-ONE study and a retrospective meta-analysis provide evidence that de-escalation is an option in this setting [39,40].

Omission of SLNB in cN0 patients and upfront BCS.

The complete omission of axillary surgery as the next de-escalation step in cN0 situations was investigated in three clinical trials restricted to BCS (Fig. 1). In 2021, the American Society of Clinical Oncology (ASCO) recommended foregoing axillary surgery in the absence of clinical benefit for older patients aged 70 and above with cN0 status and a maximum 2 cm breast cancer as well as favorable tumor biology (hormone receptor [HR]-positive, human epidermal growth factor receptor-2 [HER2]-negative tumor), regardless of whether BCS or mastectomy is performed [41]. The SOUND study demonstrated non-inferiority of this approach for a broader population [18]. In the SOUND trial, upfront BCS was performed in patients with T1 breast cancer and cN0 status, who were randomised between SLNB (n = 708) and no axillary surgery (n = 697). There were no differences in 5-year

distant disease-free survival (97.7% versus 98.0%) and overall survival (98.2% versus 98.4%). More than 90% of patients had an HR-positive/HER2-negative tumor, and 80% were peri- or postmenopausal.

The multicentric German-Austrian INSEMA study included 5154 patients with T1 or T2 breast cancer without lymph node involvement on clinical examination or axillary ultrasound. Patients were randomized to either no axillary surgery or SLNB in a 1:4 allocation. The primary endpoint of the study was invasive disease-free survival (iDFS). Secondary endpoints included overall survival, complication rates, and recurrence patterns. The evaluation of the primary study results is based on a median follow-up period of 73.6 months (6.1 years). The follow-up results showed that foregoing axillary surgery had no negative impact on survival. The estimated 5-year iDFS was 91.9% in the group without axillary surgery compared to 91.7% in the control group. Overall survival rates were comparable (98.2% versus 96.9%) [42].

The primary results of the third SLNB-omission study from the Netherlands (BOOG 2013-08) were presented at the San Antonio Breast Cancer Symposium in December 2025. This de-escalation study also met the primary endpoint (axillary recurrence rate after a median follow-up of 5 years), with the difference between the study arms below the non-inferiority margin of 5%. Surprisingly, more than 50% of study participants with HR-positive/HER2-negative disease did not receive endocrine therapy. Currently, the results are available only as an abstract (Smidt et al., late-breaking abstract, General Session #2, SABCS 2025); the full-text publication is still pending.

The published results of the SOUND and INSEMA studies have been incorporated into the updated ASCO guideline on SLNB [43]. All three studies demonstrate that omission of axillary surgery is safe in certain low-risk patients with early-stage, cN0 breast cancer. The following criteria must be met to consider omission of SLNB when the result would not influence postoperative treatment decisions (AGO ++):

- Postmenopausal women (aged ≥ 50 years) with cN0 status
- HR-positive/HER2-negative subtype with tumor grading G1/G2
- Preoperative tumor size up to 2 cm
- Planned BCS with postoperative whole-breast irradiation.

Omission of Sentinel Lymph Node Biopsy: Clinical Trials Gentilini et al. JAMA Oncology, 2023; Reimer et al., N Engl J Med, 2024; Smidt ML et al. SABCS 2025			
	SOUND Median follow-up 5.7 years	INSEMA Median follow-up 6.1 years	BOOG 2013-08 Median follow-up 5 years
Randomization	SLNB vs no SLNB (1:1)	SLNB vs no SLNB (4:1)	SLNB vs no SLNB (1:1)
n	1,405 708 SLNB vs 697 no SLNB	4,858 3,896 SLNB vs 962 no SLNB	1,572 748 SLNB vs 824 no SLNB
Population	cT ≤ 2 cm, cN0 (incl. ultrasound), invasive BC, BCT + radiotherapy	cT ≤ 5 cm (90% ≤ 2 cm), cN0 (incl. ultrasound), invasive BC, BCT + WBI	cT ≤ 2 cm (84% T1), cN0 (incl. ultrasound), invasive BC, BCT + WBT
Age	Median (IQR) 60 years (52-68)	Median (IQR) 62 years (53-68)	Mean: 61.4 years (30-85) SLNB 61.6 years (32-87) no SLNB
Intrinsic subtype, Grading, Ki-67 index	HR-pos./HER2-neg. 87.8% G3: 17.9% Ki-67 index $\geq 20\%$: 36.1%	HR-pos./HER2-neg. 95.2% G3: 3.6% Ki-67 index $> 20\%$: 12.9%	HR-pos./HER2-neg. 87.9% vs 86.4% G3: 18.4% vs 16.2%
Primary endpoint	5y DDFS: 97.7% SLNB vs 98.0% no SLNB HR 0.84 (90% CI: 0.45-1.54)	5y iDFS: 91.7% SLNB vs 91.9% no SLNB HR 0.91 (95% CI: 0.73-1.14)	RRFS 96.6% SLNB vs 94.2% no SLNB
Secondary endpoints	ARR 0.4% SLNB vs 0.7% no SLNB 5y OS 98.2% SLNB vs 98.4% no SLNB	ARR 0.3% SLNB vs 1.0% no SLNB 5y OS: 96.9% SLNB vs 98.2% no SLNB	ARR: 0.6% SLNB vs 1.1% no SLNB 5y DDFS: 96% SLNB vs 92.9% no SLNB

Fig. 1. Trials investigating omission of SLNB in the setting of upfront surgery.

Importantly, omitting SLNB must not result in suboptimal post-operative treatment recommendations and should be discussed in a multidisciplinary preoperative tumor board (AGO ++). Radiotherapy represents a controversial aspect in this context, as partial breast irradiation is currently not recommended when SLNB has not been performed due to the lack of supporting data for patients without axillary surgical staging [44]. Furthermore, uncertainties regarding lymph node status can lead to potentially indicated adjuvant therapies, such as cyclin-dependent kinase (CDK) 4/6 inhibitors, not being used appropriately. However, the results of the INSEMA and SOUND studies suggest that safe de-escalation is possible with strict patient selection [45].

2.2.2. Axillary surgery for primary node-positive (cN+) breast cancer

The optimal surgical procedure for patients with initially affected axillary lymph nodes is currently under discussion. In any case, a core-needle biopsy of the abnormal lymph node is recommended. This information should clarify the dignity of the lesion, and it is important to examine the tumor biology of the lymph node metastasis. If primary surgery is recommended at the multidisciplinary tumor board, a complete ALND is performed, which usually includes levels I and II [46]. The TAXIS trial (NCT03513614) compares ALND to a de-escalated approach of tailored axillary surgery (TAS), which includes removal of the SLN and selective removal of all palpable disease during surgery. RNI will be applied in both groups with inclusion of axilla level I/II only in the TAS-arm.

3. Surgical therapy in the neoadjuvant setting

3.1. Surgery of the breast

Patients scheduled to receive neoadjuvant chemotherapy (NACT) should be discussed in the multidisciplinary tumor board before treatment to define possible surgical options. Early marking of the tumor including detailed topographic documentation, either before start of systemic therapy, or during the first cycles is recommended. During NACT, response to treatment is evaluated using clinical examination and imaging. Surgery should be performed 4 to 8 weeks after the last administration of chemotherapy and aims at removing all visible tumor manifestations, and in case of a clinical complete response the marked area should be excised (resection “in new margins”). The recommendations regarding clear margins do not differ from those in the upfront surgery setting.

While NACT may enable breast conservation in some patients, mastectomy is recommended in case of positive margins after repeated excisions. The decision to perform a mastectomy in case of inflammatory, multicentric, and locally advanced (cT4a-c) breast cancer should be made on a case-by-case basis (AGO +/-).

3.2. Surgery of the axilla

Surgical staging of the axilla following NACT provides important prognostic information and may impact postneoadjuvant systemic and locoregional treatment decisions [47]. Nodal response has been identified as the strongest prognostic factor for invasive recurrences [48]. Residual nodal disease requires regional therapy and may lead to additional systemic treatment, specifically in triple-negative or HER2-positive patients or BRCA mutation carriers [49–51].

SLNB is recommended for all patients staged as cN0 and should be performed after NACT. Retrospective studies have shown that axillary lymph node involvement is rare (<2 %) in clinically node-negative HER2-positive or triple-negative breast cancer patients, who achieve pathological complete response (pCR) in the breast [52]. Omission of SLNB is under investigation in three prospective cohort studies, which include patients with cT1 and cT2 disease who undergo breast-conserving therapy [53]. The EUBREAST-01 and ASLAN studies have already completed accrual.

Despite initial concerns regarding the safety of SLNB after NACT in patients with biopsy-proven node-positive disease converting to ycN0 [54], the AXSANA study, presented at the San Antonio Breast Cancer Conference 2025, provided evidence from the largest available prospective multicenter cohort study, including 288 study sites across 26 countries, that less invasive staging procedures are safe in terms of regional control. No differences were observed between ALND and less invasive procedures, or between SLNB and TAD [55,56]. The results confirmed findings from previous smaller studies and retrospective series [57–62]. In light of these mature data, the AGO revised its 2025 recommendations and defined targeted axillary dissection (TAD) as the preferred procedure for surgical axillary staging after NACT (AGO ++). SLNB and TLNB are also accepted techniques (AGO +), while ALND is no longer recommended as a standard to stage the axilla (AGO +/-) (Fig. 2). The lower SLNB rating compared to TAD is explained by a higher detection failure rate and lower accuracy, with potential impact on invasive recurrences, as observed in some studies [58]. Some concern remains for patients with 4 or more clinically involved lymph nodes at the time of diagnosis, which translates into a slightly lower recommendation grade for TAD in these patients (AGO +). In this context, it is worth noting that a higher number of suspicious lymph nodes (e.g., 4 or more) does not necessarily translate to a cN2 (or higher) nodal stage, since the clinical (cN) and pathological (pN) nodal status classification are based on different assessment principles. The cN is determined using physical examination and imaging and reflects the presence and clinical characteristics of suspicious lymph nodes (e.g., mobility, fixation), but is not based on the number of involved lymph nodes. In contrast, the postoperative pN status depends on the number of metastatic lymph nodes. Interestingly, Loveland-Jones et al. reported that presentation with ≥ 4 abnormal nodes on ultrasound did not predict higher false-negative rate of TAD [63].

The recommendation to perform TAD in patients with occult breast cancer and axillary metastasis (axCUP) was newly introduced into the AGO guidelines (AGO +). In addition, TAD was also acknowledged as an individual option in selected patients with inflammatory breast cancer (AGO +/-).

Recently published data from 2596 patients included in the AXSANA study showed that the detection rate of the target lymph node (TLN) was highest in patients whose TLNs were marked with a marker suitable for probe-guided detection before NACT [64]. The use of clips for TLN marking is associated with higher rates of marker loss [65–70]. Therefore, probe-guided detection is rated as highly effective in the updated recommendations (AGO +). The most prominent suspicious node should be marked, while the decision to mark more nodes in case of higher nodal involvement should be made on a case-by-case basis (AGO +/-) (Fig. 3).

ALND should be performed in patients who remain clinically node-positive after NACT (cN+) (AGO +). It is worth noting that more than 20% of patients with residual suspicious lymph nodes upon ultrasound after NACT are, in fact, ypN0 [71]. In patients with clinically node-negative disease and macrometastatic SLN/TLN involvement ($\geq$ ypN1a), ALND is the preferred treatment modality (AGO +). The ongoing randomized Alliance 11,202 study compares completion ALND with regional radiotherapy in patients with residual nodal disease after NACT and will provide high-level evidence on the optimal treatment. Despite substantial additional lymph node involvement in the case of a microscopic SLN/TLN involvement, a completion ALND does not provide meaningful information for post-neoadjuvant treatment modifications [72,73]. According to a large retrospective analysis, ALND showed no benefit in disease-free survival or overall survival for patients with microscopic nodal involvement after NACT [74]. Therefore, the AGO Breast Committee does not recommend ALND in patients with ypN1mi (sn/tad) status as standard of care (AGO +/-). If only isolated tumor cells are identified (ypN0(i+) [sn/tad]), ALND should not be performed (AGO -) [72,75].



© AGO e. V.
in der DGGO e.V.
sowie
in der DKG e.V.

Guidelines Breast
Version 2026.1E

In collaboration
with:



www.ago-online.de

FORSCHEN
LEHREN
HEILEN

Axillary Surgery in the setting of NACT (cN+)

cN status (before NACT)	pN status (before NACT)	ycN status (after NACT)	Axillary surgery (after NACT)	AGO	ypN status (after NACT and surgery)	Surgical consequence based on histopathology	Oxford		AGO
							LoE	GR	
cN+ *	pN+ _{CNB}	ycN0	ALND	+/-	ypN0 / ypN+	None	2b	B	++
			TAD	++ **	ypN0	None	2b	B	+
					ypN0 (i+)	ALND	2b	B	-
					ypN1mi	ALND	2b	B	+/-
					ypN+	ALND	2b	B	+
			SLNE	+	ypN0	None	2b	B	+
					ypN0 (i+)	ALND	2b	B	-
					ypN1mi	ALND	2b	B	+/-
					ypN+	ALND	2b	B	+
			TLNE	+	ypN0	None	2b	B	+
					ypN0 (i+)	ALND	3b	B	-
					ypN1mi	ALND	2b	B	+/-
					ypN+	ALND	2b	B	+
		ycN+ ***	ALND	+	ypN0 / ypN+	None	2b	B	++

* Study participation in AXSANA recommended; ** in case of initially 1-3 suspicious nodes; *** Cave: In 21.1% false-positive findings, consider CNB/TAD

Fig. 2. Current recommendations of the AGO Breast Committee regarding axillary surgery in patients with initially node-positive breast cancer in the neo-adjuvant setting.

Targeted Axillary Dissection (TAD) = TLNE + SLNE				
		Oxford		
		LoE	GR	AGO
Core needle biopsy and marking of suspicious lymph nodes		2b	B	++
Marking of multiple nodes if more than one node is suspicious		2b	B	+/-
TLN detection rate is highest when markers suitable for probe-guided detection are used before NACT*		2b	B	+
TAD in case of 1-3 suspicious nodes before NACT and ycN0		2b	B	++
TAD in case of ≥ 4 suspicious nodes before NACT and ycN0		2b	B	+
TAD in case of inflammatory breast cancer and cN1 → ycN0		3b	C	+/-
TAD in case of occult breast cancer (axCUP) and ycN0		3b	C	+
Full workup using step sections of ≤ 500 µm on paraffin embedded tissue		5	D	++
Immunohistochemistry for ITC detection		2b	D	-
SLNE alone in case of a non-detectable TLN and ycN0		5	D	+
ALND in case of pre- or intraoperatively non-detectable TLN and SLN		5	D	+
Further intervention to retrieve lost marker (incl. after ALND)		5	D	-

* Study participation in AXSANA recommended.

Fig. 3. Current recommendations of the AGO Breast Committee regarding targeted axillary dissection.

4. Oncoplastic surgery and breast reconstruction

4.1. Oncoplastic surgery

The definition of oncoplastic surgery (OPS) remains unchanged in the updated AGO treatment recommendations and refers to the use of plastic surgical techniques at the time of tumor removal to enhance aesthetic and quality of life outcomes without compromising oncological safety with the focus on favorable scar placement, adequate soft tissue formation, selection of an appropriate reconstructive technique (considering radiation therapy), and contralateral symmetrization.

Compared to BCS, OPS has the same oncological safety and a similar complication rate [76–79]. In addition, in selected cases, OPS can

replace mastectomy, particularly in the presence of multifocal and multicentric disease [80,81]. In breast hypertrophy, tumor-adapted reduction mammoplasty before radiotherapy is associated with fewer complications than secondary reduction surgery after irradiation; however, secondary reduction appears feasible in terms of complication rate [82].

A recently published systematic review and meta-analysis, including 17 studies and 1893 chest wall perforator flaps (CWPF) for partial breast reconstruction in patients receiving BCS, demonstrated oncological safety of the procedure [83]. The most frequently used flap was the lateral intercostal artery perforator (LICAP) flap (1016 cases), followed by the lateral thoracic perforator (LTAP) flap (297 cases), and the anterior intercostal artery perforator (AICAP) flap in 192 patients. The

recipient-site complication rate was 13% and similar across different flap types. Flap loss occurred rarely (1%), and patient satisfaction was high. In 13%, re-excision was necessary for oncological reasons, and completion mastectomy was performed in 1.5% of patients. CWPf may be offered to avoid a mastectomy or contralateral symmetrization surgery, especially in patients with small to medium-sized breasts.

4.2. Breast reconstruction after mastectomy: techniques and current developments

Aesthetic flat closure (AFC) has become an increasingly popular option among patients who choose not to undergo breast reconstruction following mastectomy. Despite its growing acceptance, there remains a paucity of robust evidence to inform optimal surgical techniques or to comprehensively assess patient-reported outcomes [84,85]. With regard to reconstructive options following mastectomy, implant-based (heterologous) reconstruction as well as autologous techniques—including pedicled and free flap procedures—are recommended with an equal level of recommendation. (AGO +). The choice of method should be guided by individual patient factors, tumor characteristics, and, most importantly, the patient's preferences and expectations [86,87].

4.3. Infection prevention

Current guidelines recommend limiting perioperative intravenous antibiotic prophylaxis to a maximum of 24 h [88–90]. (AGO +) While a meta-analysis published in 2024, encompassing 19,301 patients, indicated that extended antibiotic prophylaxis may confer some benefits compared with intraoperative administration alone or regimens limited to 24 h [91], in light of notable methodological limitations and potential sources of bias within several of the included studies, prolonged intravenous antibiotic therapy beyond 24 h should be considered only as an alternative approach rather than routine practice (AGO +/-).

Furthermore, the intraoperative topical administration of a prophylactic antibiotic (e.g., gentamicin) and/or the use of an antiseptic rinse is recommended (AGO +). An emerging approach involves collecting a culture from the surgical drainage seven days postoperatively and initiating targeted antibiotic therapy guided by the resulting antibiogram. This personalized strategy can be considered on an individual, case-by-case basis [92] (AGO +/-).

4.4. Prevention of seroma and hematoma

In recent years, the number of publications and the corresponding evidence supporting the use of tranexamic acid for seroma prevention, as well as for reducing postoperative bleeding in implant-based reconstruction, has grown continuously. The benefits of tranexamic acid have now been demonstrated also in complex breast surgery, such as mastectomy, tumor-adapted reduction mammoplasty, or other oncoplastic procedures. Tranexamic acid can be applied topically or systemically (IV/oral) (AGO +). Possible regimens include IV administration within the first 24 h, followed by oral dosing (total 1–3 g over 1–5 days) or topical application of 3 g in 100 ml NaCl intraoperatively [93–96]. Glucocorticoids to reduce the risk of seroma may also be considered (AGO +/-). A recently published meta-analysis suggests that methylprednisolone (IV 100–125 mg, given 1 h before surgery or locally with 80 mg delivered through the drain into the wound cavity with the drain clamped for 24 h) or 100 mg hydrocortisone IV immediately prior to surgery can be recommended (AGO +/-) [97].

4.5. Direct-to-implant reconstruction

Unfortunately, in skin-sparing (SSM) or nipple-sparing mastectomy (NSM), large prospective randomized controlled trials comparing acellular dermal matrices (ADM) versus absorbable or non-absorbable (titanium-coated TiLOOP) meshes versus no mesh are still lacking.

Therefore, the AGO Breast Committee cannot issue a differentiated recommendation for one approach over another. However, based on current literature and clinical practice, the rate of major complications appears to be higher with ADM use than with mesh alone [98,99]. Zhang et al. demonstrated in a meta-analysis that seroma rates, infections, and implant losses were higher with ADM use than with a titanium-coated TiLOOP mesh [100].

Endoscopic techniques in breast surgery have gained increasing popularity, particularly for NSM. Endoscopic or robot-assisted NSM has been performed predominantly in Asia over the past decade but has gradually gained traction in Europe (AGO +/-). Before initiating these techniques, a standard of care should be established. The 2025 consensus by Ryu et al. summarizes indications and contraindications well: indication for $\leq$ cT2, cN0, $\leq$ cup-C, tumor distance to skin $>$ 5 mm; contraindications include invasion of the nipple-areolar complex, a T4 tumor, inflammatory carcinoma, and marked ptosis [101].

ICG for the prevention of mastectomy flap necrosis can provide intraoperative assessment of skin perfusion. A recent published meta-analysis from 8 studies with 1252 patients reported a significant reduction of skin flap necrosis, severe flap necrosis and reoperation. Given the robust data, AGO hence recommends the use of ICG with a grade of recommendation AGO + [102]. The only other technique graded AGO + for prevention of skin flap necrosis is locally used nitroglycerin [103]. Negative pressure wound therapy (NPWT) has been investigated recently amongst other trials in a meta-analysis of 31 studies (8 RCTs and 23 observational studies) for preventing wound-healing disturbances, mastectomy flap necrosis, and infection of the operative field, particularly in patients with BMI $>$ 30, and may be used on a case-by-case basis (AGO +/-) [104,105].

4.6. Autologous fat grafting (AFG)

If implant-based reconstruction is not desired or only a volumetric deficit needs to be addressed, autologous fat transfer is considered. There is now a wide range of indications, including improving skin trophicity after radiotherapy, rehabilitating a volumetric defect after nipple-sparing mastectomy or BCS, or rebuilding an entire breast with fat. There is no evidence requiring a specific interval to be observed after breast cancer surgery before fat grafting. Data on whether fat grafting increases recurrence risk when two years elapse between BCS and AFG exist only in animal models [106].

4.7. Autologous breast reconstruction

The deep inferior epigastric artery perforator (DIEP) flap is certainly the standard for autologous breast reconstruction with a free flap (AGO ++). Other options include the free gracilis flap (transverse myocutaneous gracilis, TMG) (AGO +) [107] or the profunda artery perforator (PAP) flap (AGO +) [108,109], the latter two serving as secondary options.

5. Summary

In the 2026 update of the AGO Breast Committee recommendations, the focus of the surgery-related chapters was on reducing the extent of surgical therapy in the axilla. Omitting SLNB should be recommended in patients with low-risk breast cancer treated with upfront BCS with whole-breast irradiation, in whom the detection of a macrometastatic sentinel node would not impact postoperative therapy. In the neo-adjuvant setting, substantial modifications to the recommendations concerning de-escalated axillary surgery in patients with initially node-positive disease were endorsed. For patients with 1–3 suspicious nodes at diagnosis and converting to ycN0, TAD is the technique of choice (AGO ++), but SLNB and TLND are also possible options (AGO +). Marking of target lymph node(s) with markers suitable for probe-guided detection before NACT may increase detection rates and rates of a successful TAD/

TLNB.

Author contributions

CS, MBP, MT, TR, TK, VBR: Conceptualization; Writing - original draft.

All authors: Conceptualization; Writing - review & editing.

Financial support

No financial support was provided for this work.

Conflicts of interest

Maggie Banys-Paluchowski: honoraria for lectures and advisory role from: Roche, Novartis, Pfizer, pfm, Eli Lilly, Onkowsen, Seagen, AstraZeneca, Eisai, Amgen, Samsung, Canon, MSD, GSK, Daiichi Sankyo, Gilead, Sirius Medical, Syantra, resitu, Pierre Fabre, ExactSciences, Menarini Stemline, if-kongress, Jörg Eickeler, Aurikamed, KW Medipoint, medupdate, neoConnect, meet the experts, ClinSol, Kelcon; Study support: Bundesministerium für Forschung, Technologie und Raumfahrt (BMFTR, ehem. BMBF), Damp Stiftung, Claudia von Schilling Foundation for Breast Cancer Research, Ehmann-Stiftung Savognin, Eugen & Irmgard Hahn Stiftung, Korean Breast Cancer Society, EndoMag, Mammotome, MeritMedical, Sirius Medical, Gilead, Hologic, ExactSciences; Travel expenses: Eli Lilly, ExactSciences, Pierre Fabre, Pfizer, Daiichi Sankyo, Roche, AstraZeneca, Novartis; Memberships: AGO Kommission Mamma, DEGUM III Gremium Mammasonographie, Vorstand EUBREAST e.V., Vorstand AWOgyn, Vorstand Deutsche Gesellschaft für Senologie als Co-Kongresspräsidentin 2025, Deutsche Gesellschaft für Gynäkologie und Geburtshilfe, Associate Editor Archives of Obstetrics and Gynecology, Associate Editor European Journal of Surgical Oncology.

Given her role as Associate Editor Maggie Banys-Paluchowski had no involvement in the peer-review of this article and has no access to information regarding its peer review. Full responsibility for the editorial process for this article was delegated to another journal editor.

Vesna Bjelic-Radisic (last 3 years): Advisory Board: Agendia, pfm Medical, Gilead Science, Lilly, Pfizer, pfm Medical, Merit Medical, Titanium Textiles, Mammotome; Congress support: Mammotome, Pfizer, pfm medical, Endomag Mentor, Polytech, Sirius Medical, CE Ästhetic; Lecture honoraria: Agendia, Science, GSK, Jörg Eickeler, Pfizer, pfm medical, Roche; Membership and role in academic institutions: Deutsche Gesellschaft für Ultraschall in der Medizin, Deutsche Gesellschaft für Senologie, Deutsche Krebsgesellschaft, Deutsche Gesellschaft für Gynäkologie und Geburtshilfe (DGGG) Arbeitsgemeinschaft Gynäkologische Onkologie (AGO), Arbeitsgemeinschaft für ästhetische, plastische und wiederherstellende Operationsverfahren in der Gynäkologie (AWOgyn) (Chair), European Breast Cancer Research Association of Surgical Trialists (EUBREAST), European Society of Medical Oncology (ESMO), European Organisation for Research and Treatment of Cancer (Chair Breast and Gynecological QoL Group).

Marc Thill: Conflicts of interest of the last 3 years: Advisory Board: Agendia, Amgen, AstraZeneca, Aurikamed, Becton/Dickinson, ClearCut, Daiichi Sankyo, Exact Sciences, Gilead Science, GSK, Hexal, Lilly, MSD, Novartis, Onkowsen, Pfizer, pfm Medical, Roche, Saman Tree, Seagen, Sirius Medical, Sysmex, Titanium Textiles; Manuscript support: Amgen, Cairn Surgical, ClearCut, pfm medical, Servier; Travel expenses: Amgen, Art Tempi, AstraZeneca, Clearcut, Daiichi Sankyo, Exact Sciences, Gilead, Hexal, I-Med-Institute, Lilly, Menarini Stemline, MSD, Neodynamics, Novartis, Pfizer, pfm Medical, Roche, RTI Surgical, Seagen, Zuellig Pharma; Congress support: Amgen, AstraZeneca, Daiichi Sanyko, Gilead, Hexal, Lilly, Menarini Stemline, Novartis, Pfizer, pfm medical, Roche, Sirius Medical; Lecture honoraria: Agendia, Amgen, Art Tempi, AstraZeneca, Endomag, Exact Sciences, Gilead Science, GSK, Hexal, I-Med-Institute, Jörg Eickeler, Johnson and Johnson, Laborarztpraxis

Walther et al. Lilly, Medscape, Menarini Stemline, MSD, Novartis, Onkowsen, Pfizer, pfm medical, Roche, Seagen, Sirius Medical, StreamedUp, Sysmex, Zuellig Pharma; Trial Funding (institutional): Endomag, Exact Sciences; Trial honoraria (institutional): AstraZeneca, CairnSurgical, Clearcut, Novartis, Novus Scientific, pfm medical, Roche, RTI Surgical; Membership and role in academic institutions: Berufsverband der Frauenärzte e. V., Deutsche Gesellschaft für Ultraschall in der Medizin, Deutsche Gesellschaft für Senologie, Deutsche Krebsgesellschaft, Deutsche Gesellschaft für Gynäkologie und Geburtshilfe (DGGG) (Board of directors), Arbeitsgemeinschaft Gynäkologische Onkologie (AGO), Breast Competence Club der European Academy of Senology, Arbeitsgemeinschaft Gynäkologische Endoskopie (AGE), European Society of Gynecological Endoscopy (ESGE), Arbeitsgemeinschaft für ästhetische, plastische und wiederherstellende Operationsverfahren in der Gynäkologie (AWOgyn) (Board of directors), Bundesarbeitsgemeinschaft Leitender Ärztinnen und Ärzte in der Frauenheilkunde und Geburtshilfe e.V. (Board of directors), European Breast Cancer Research Association of Surgical Trialists (EUBREAST), OncoNet Rhein-Main e.V. (Board of directors), Hessische Krebsgesellschaft, European Society of Medical Oncology (ESMO).

Thorsten Kühn: MSD, Exact Sciences, Novartis, Lilly, Merit Medical, Sirius Pintuition, Endomag, Daiichi Sanyo.

Juliane Hörner-Rieber: honoraria from ViewRay Inc., Pfizer Inc., Accuray Sarl, Sanofi, and Astra Zeneca, as well as travel reimbursement from Varian Medical Systems and research grants from IntraOP Medical and Varian Medical Systems outside the submitted work.

David Krug has received honoraria from Astra Zeneca, best practice onkologie, ESO, ESMO, Gilead, med update, Merck Sharp & Dohme, Novartis, onkowsen, Pfizer and PINK gegen Brustkrebs, served on advisory boards for Gilead and has received institutional research funding from Stiftung Deutsche Krebshilfe und Merck KGaA.

Isabell Witzel: COIs: Honoraria from Astra Zeneca, Gilead, Pfizer, Lilly, Novartis, Roche, Daiichi Sankyo, Exact Sciences.

Jens Huober: Honoraria: Lilly, Novartis, Roche, Pfizer, AstraZeneca, Gilead, Daiichi, Stemline, MSD, Abbvie; Consulting, advisory relationship: Lilly, Novartis, Roche, Pfizer, AstraZeneca, Gilead, Daiichi, Abbvie; Travel expenses: Roche, Daiichi, Gilead, Astra Zeneca.

Michael P. Lux has received honoraria from Abbvie, ClinSol GmbH & Co. KG, Lilly, Pfizer, Roche, MSD, Hexal, Novartis, AstraZeneca, Eisai, Exact Sciences, Agendia, Daiichi Sankyo, Grünenthal, Gilead, Stemline, Samantree and Endomag for advisory boards, lectures, and travel support.

Peter A. Fasching reports personal fees from Novartis, grants from Biontech, grants and personal fees from Pfizer, personal fees from Daiichi-Sankyo, personal fees from Astra Zeneca, personal fees from Eisai, personal fees from Merck Sharp & Dohme, grants from Cepheid, personal fees from Lilly, personal fees from SeaGen, personal fees from Roche, personal fees from Agendia, personal fees from Gilead, personal fees from Mylan, personal fees from Menarini, personal fees from Veracyte, personal fees from GuardantHealth, during the conduct of the study; and Translational Research in Oncology (TRIO).

Rupert Bartsch: Honoraria: Amgen, Astra-Zeneca, BMS, Daiichi-Sankyo, Eisai, Eli-Lilly, Gilead, Gruenthal, MSD, MedMedia, Novartis, Pfizer, Pierre-Fabre, Roche, Stemline; Research Support (insitutiinal): Astra-Zeneca, Daiichi-Sanyko, MSD; Travel Support: Astra-Zeneca, Daiichi-Sankyo, Eli-Lilly, Gilead, MSD, Novartis, Pfizer, Roche; Memberships: AGO Kommission Mamma, Austrian Breast and Colorectal Cancer Study Group, Austrian Society of Haematology and Oncology, Austrian Society of Senology, European Society of Medical Oncology (ESMO).

Jens-Uwe Blohmer: AstraZeneca, Daiichi Sankyo, Gilead, Lilly, Menarini Stemline, MSD, Novartis, Roche.

Andreas Hartkopf: Speakers Bureau: Roche, Novartis, Lilly, MSD, AstraZeneca, DaiichiSankyo, Seagen, GSK, ExactScience, Gilead, Menarini Stemline, Pfizer, Eisai; Honoraria: Roche, Novartis, Lilly, MSD, AstraZeneca, Seagen, GSK, ExactScience, Riemsers, Teva, Onkowsen,

Gilead, Menarini Stemline, Pfizer, Amgen, Pierre Fabre, Eisai, Daichi-Sankyo; Consulting or advisory role: Roche, Novartis, MSD, AstraZeneca, GSK, ExactScience, Riemser, Teva, Onkowsen, Gilead, Menarini Stemline, Pfizer, Amgen, Pierre Fabre, Daichi-Sankyo; Travel support: Roche, Novartis, Lilly, AstraZeneca, GSK, ExactScience, Gilead, Menarini Stemline, Pfizer, Daichi-Sankyo; Receipt of grants/research supports: ExactScience, Veracyte; Honoraria for publication authorship or co-authorship: AstraZeneca, Menarini Stemline.

Marcus Schmidt reports receiving personal fees from AstraZeneca, BioNTech, Daiichi Sankyo, Eisai, Eurobio, Exact Sciences, Gilead, Lilly, Menarini-Stemline, Molecular Health, MSD, Novartis, Pantarhei Bioscience, Pfizer, Pierre Fabre, and Roche. His institution has received research funding from AstraZeneca, BioNTech, Eisai, Genentech, the German Breast Group, Novartis, Palles, Pantarhei Bioscience, Pfizer, Pierre Fabre, and Roche. He is also listed as an inventor on patents EP 2390370 B1 and EP 2951317 B1.

Christine Solbach (last 3 years): Advisory role: Roche, Menarini Stemline Deutschland GmbH, MSD; Lecture/speaker/engagement fees: Dialog Service GmbH, Jörg Eickeler, MedConcept, Meet the Expert Academy, Medela, Samsung, Novartis, Roche, Pfizer, AstraZeneca, LÄKH.

Other authors declare no conflicts of interest.

References

- [1] Thill M, Friedrich M, Kolberg-Liedtke C, Albert US, Banys-Paluchowski M, Bauerfeind I, et al. AGO recommendations for the diagnosis and treatment of patients with locally advanced and metastatic breast cancer: update 2021. *Breast Care* 2021;16(3):228–35.
- [2] Ditsch N, Kolberg-Liedtke C, Friedrich M, Jackisch C, Albert US, Banys-Paluchowski M, et al. AGO recommendations for the diagnosis and treatment of patients with early breast cancer: update 2021. *Breast Care* 2021;16(3):214–27.
- [3] Reimer T, Kuehn T, Mueller V, Ditsch N, Fehm T, Albert US, et al. AGO breast commission recommendations for the surgical therapy of breast cancer: Working group on gynecologic cancers (AGO) update 2025. *Eur J Surg Oncol* 2025;51(11):110445.
- [4] Park-Simon TW, Müller V, Albert US, Banys-Paluchowski M, Bartsch R, Bauerfeind I, et al. AGO recommendations for early breast cancer: update 2026. *Breast Care* 2026.
- [5] Thill M, Müller V, Fehm T, Albert US, Banys-Paluchowski M, Bartsch R, et al. AGO recommendations for the diagnosis and treatment of patients with locally advanced and metastatic breast cancer: update 2026. *Breast Care* 2026.
- [6] Rajan KK, Fairhurst K, Birkbeck B, Novintan S, Wilson R, Savovic J, et al. Overall survival after mastectomy versus breast-conserving surgery with adjuvant radiotherapy for early-stage breast cancer: meta-analysis. *BJS Open* 2024;8(3).
- [7] Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. *N Engl J Med* 2002;347(16):1233–41.
- [8] Gulis K, Ellbrant J, Bendahl PO, Svensjö T, Ryden L. Health-related quality of life by type of breast surgery in women with primary breast cancer: prospective longitudinal cohort study. *BJS Open* 2024;8(3).
- [9] Holzel D, Schlesinger-Raab A, Schubert-Fritschle G, Halfter K. Prolonged time to breast cancer surgery and the risk of metastasis: an explorative simulation analysis using epidemiological data from Germany and the USA. *Breast Cancer Res Treat* 2025;211(1):151–60.
- [10] Allemani C, Minicozzi P, Morawski B, Lima CA, Bennett D, Pongnikorn D, et al. Global variation in patterns of care and time to initial treatment for breast, cervical, and ovarian cancer from 2015 to 2018 (VENUSCANCER): a secondary analysis of individual records for 275 792 women from 103 population-based cancer registries in 39 countries and territories. *Lancet* 2025;406(10517):2325–48.
- [11] Banys-Paluchowski M, Kuhn T, Masannat Y, Rubio I, de Boniface J, Ditsch N, et al. Localization techniques for non-palpable breast lesions: current status, knowledge gaps, and rationale for the MELODY study (EUBREAST-4/IBRA-NET, NCT 05559411). *Cancers (Basel)* 2023;15(4).
- [12] Athanasiou C, Mallidis E, Tuffaha H. Comparative effectiveness of different localization techniques for non-palpable breast cancer. A systematic review and network meta-analysis. *Eur J Surg Oncol* 2022;48(1):53–9.
- [13] Davey MG, O'Donnell JPM, Boland MR, Ryan EJ, Walsh SR, Kerin MJ, et al. Optimal localization strategies for non-palpable breast cancers - A network meta-analysis of randomized controlled trials. *Breast* 2022;62:103–13.
- [14] Banys-Paluchowski M, Rubio IT, Karadeniz Cakmak G, Esgueva A, Krawczyk N, Paluchowski P, et al. Intraoperative ultrasound-guided excision of non-palpable and palpable breast cancer: systematic review and meta-analysis. *Eur J Ultrasound* 2022.
- [15] Pantiora E, Jazrawi A, Hersi AF, Abdsaleh S, Ahlstedt H, Molnar E, et al. Magnetic seed vs guidewire breast cancer localization with magnetic lymph node detection: a randomized clinical trial. *JAMA Surg* 2024;159(3):239–46.
- [16] Hersi AF, Eriksson S, Ramos J, Abdsaleh S, Warnberg F, Karakatsanis A. A combined, totally magnetic technique with a magnetic marker for non-palpable tumour localization and superparamagnetic iron oxide nanoparticles for sentinel lymph node detection in breast cancer surgery. *Eur J Surg Oncol* 2019;45(4):544–9.
- [17] Pantiora E, Sampaio F, Jazrawi A, Warnberg F, Eriksson S, Karakatsanis A. Magnetic seed versus guidewire-based breast cancer localization with magnetic lymph node detection: cost-minimization analysis. *Br J Surg* 2025;112(12).
- [18] Wang GL, Tsikouras P, Zuo HQ, Huang MQ, Peng L, Bothou A, et al. Radioactive seed localization and wire guided localization in breast cancer: a systematic review and meta-analysis. *J Buon* 2019;24(1):48–60.
- [19] Pouw B, de Wit-van der Veen LJ, Stokkel MP, Loo CE, Vrancken Peeters MJ, Valdes Olmos RA. Heading toward radioactive seed localization in non-palpable breast cancer surgery? A meta-analysis. *J Surg Oncol* 2015;111(2):185–91.
- [20] Volders JH, Haloua MH, Krekel NM, Negenborn VL, Kolk RH, Lopes Cardozo AM, et al. Intraoperative ultrasound guidance in breast-conserving surgery shows superiority in oncological outcome, long-term cosmetic and patient-reported outcomes: final outcomes of a randomized controlled trial (COBALT). *Eur J Surg Oncol* 2017;43(4):649–57.
- [21] Manhoobi IP, Bodilsen A, Nijkamp J, Pareek A, Tramm T, Redstedt S, et al. Diagnostic accuracy of radiography, digital breast tomosynthesis, micro-CT and ultrasound for margin assessment during breast surgery: a systematic review and meta-analysis. *Acad Radiol* 2022;29(10):1560–72.
- [22] Zaborowski AM, Roe S, Rothwell J, Evoy D, Geraghty J, McCartan D, et al. A systematic review of oncological outcomes after nipple-sparing mastectomy for breast cancer. *J Surg Oncol* 2023;127(3):361–8.
- [23] Schwartz GF, Giuliano AE, Veronesi U, Consensus Conference C. Proceeding of the consensus conference of the role of sentinel lymph node biopsy in carcinoma of the breast April 19–22, 2001, Philadelphia, PA, USA. *Breast J* 2002;8(3):124–38.
- [24] Rao R, Euhus D, Mayo HG, Balch C. Axillary node interventions in breast cancer: a systematic review. *JAMA* 2013;310(13):1385–94.
- [25] Hartmann S, Plonus ML, Schulte G, Stuber J, Gerber B, Reimer T. Indocyanine green marking of axillary sentinel lymph nodes in early breast cancer. *Geburtshilfe Frauenheilkd* 2025;85(6):631–8.
- [26] Jazrawi A, Pantiora E, Abdsaleh S, Ng CL, Zouzou A, Gagliardi T, et al. Prospective evaluation of MRI artefacts following breast conserving surgery and sentinel lymph node dissection with the magnetic technique. *Eur J Surg Oncol* 2025;51(1):109368.
- [27] Lyman GH, Temin S, Edge SB, Newman LA, Turner RR, Weaver DL, et al. Sentinel lymph node biopsy for patients with early-stage breast cancer: American society of clinical oncology clinical practice guideline update. *J Clin Oncol* 2014;32(13):1365–83.
- [28] Giuliano AE, McCall L, Beitsch P, Whitworth PW, Blumencranz P, Leitch AM, et al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: the American college of surgeons oncology group Z0011 randomized trial. *Ann Surg* 2010;252(3):426–32. discussion 432–423.
- [29] Giuliano AE, Hunt KK, Ballman KV, Beitsch PD, Whitworth PW, Blumencranz PW, et al. Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial. *JAMA* 2011;305(6):569–75.
- [30] Giuliano AE, Ballman KV, McCall L, Beitsch PD, Brennan MB, Kelem PR, et al. Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis: the ACOSOG Z0011 (Alliance) randomized clinical trial. *JAMA* 2017;318(10):918–26.
- [31] Tinterri C, Gentile D, Gatzemeier W, Sagana A, Barbieri E, Testori A, et al. Preservation of axillary lymph nodes compared with complete dissection in T1–2 breast cancer patients presenting one or two metastatic sentinel lymph nodes: the SINODAR-ONE multicenter randomized clinical trial. *Ann Surg Oncol* 2022;29(9):5732–44.
- [32] de Boniface J, Filtenborg Tvedskov T, Ryden L, Szulkin R, Reimer T, Kuhn T, et al. Omitting axillary dissection in breast cancer with sentinel-node metastases. *N Engl J Med* 2024;390(13):1163–75.
- [33] Reimer T, Stachs A, Veselinovic K, Kuehn T, Heil J, Polata S, et al. Axillary surgery in patients with sentinel node macrometastases: secondary results of the randomized INSEMA trial. *NPJ Breast Cancer* 2026;12(1):19.
- [34] de Boniface J, Frisell J, Andersson Y, Bergkvist L, Ahlgren J, Ryden L, et al. Survival and axillary recurrence following sentinel node-positive breast cancer without completion axillary lymph node dissection: the randomized controlled SENOMAC trial. *BMC Cancer* 2017;17(1):379.
- [35] Goyal A, Mann GB, Fallowfield L, Duley L, Reed M, Dodwell D, et al. POSNOC-POSITIVE sentinel NODe: adjuvant therapy alone versus adjuvant therapy plus clearance or axillary radiotherapy: a randomised controlled trial of axillary treatment in women with early-stage breast cancer who have metastases in one or two sentinel nodes. *BMJ Open* 2021;11(12):e054365.
- [36] Alkner S, Wieslander E, Lundstedt D, Berg M, Kristensen I, Andersson Y, et al. Quality assessment of radiotherapy in the prospective randomized SENOMAC trial. *Radiother Oncol* 2024;197:110372.
- [37] Banys-Paluchowski M, Rubio IT, Ditsch N, Eickeler J, Gentilini OD, Kuhn T. Real de-escalation or escalation in disguise? *Breast* 2023;69:249–57.

- [38] Kunkler IH, Russell NS, Anderson N, Sainsbury R, Dixon JM, Cameron D, et al. Ten-year survival after postmastectomy chest-wall irradiation in breast cancer. *N Engl J Med* 2025;393(18):1771–83.
- [39] Tinteri C, Canavese G, Gatzemeier W, Barbieri E, Bottini A, Sagana A, et al. Sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer patients undergoing mastectomy with one to two metastatic sentinel lymph nodes: sub-analysis of the SINODAR-ONE multicentre randomized clinical trial and reopening of enrolment. *Br J Surg* 2023.
- [40] Alamoodi M, Patani N, Mokbel K, Wazir U, Mokbel K. Reevaluating axillary lymph node dissection in total mastectomy for low axillary burden breast cancer: insights from a meta-analysis including the SINODAR-ONE trial. *Cancers (Basel)* 2024;16(4).
- [41] Brackstone M, Baldassarre FG, Perera FE, Cil T, Chavez Mac Gregor M, Dayes IS, et al. Management of the axilla in early-stage breast cancer: ontario health (Cancer Care Ontario) and ASCO guideline. *J Clin Oncol* 2021;39(27):3056–82.
- [42] Reimer T, Stachs A, Veselinovic K, Kuhn T, Heil J, Polata S, et al. Axillary surgery in breast cancer - primary results of the INSEMA trial. *N Engl J Med* 2025;392(11):1051–64.
- [43] Park KU, Somerfield MR, Anne N, Brackstone M, Conlin AK, Couto HL, et al. Sentinel lymph node biopsy in early-stage breast cancer: ASCO guideline update. *J Clin Oncol* 2025;43(14):1720–41.
- [44] Borm KJ, Horner-Rieber J, Duma NM, Budach W, Piroth MD, Krug D. Breast cancer expert panel of the German society of radiation oncology D: de-Escalation strategies in early breast cancer: implications of sentinel lymph node biopsy omission for adjuvant radiotherapy. *Strahlenther Onkol* 2025;201(6):573–6.
- [45] Morrow M. Sentinel-lymph-node biopsy in early-stage breast cancer - is it obsolete? *N Engl J Med* 2025;392(11):1134–6.
- [46] German S3 Breast Cancer Guideline. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Früherkennung, Diagnostik, Therapie und Nachsorge des Mammakarzinoms, Langversion 5.0, 2025, AWMF-Registernummer: 032-045OL. <https://www.leitlinienprogramm-onkologie.de/leitlinien/mammakarzinom/>. [Accessed 7 March 2026].
- [47] Tauber N, Amann N, Dannehl D, Deutsch TM, Dimpfl M, Fasching P, et al. Therapy of early breast cancer: current status and perspectives. *Arch Gynecol Obstet* 2025.
- [48] Gerber B, Schneeweiss A, Mobus V, Golatta M, Tesch H, Krug D, et al. Pathological response in the breast and axillary lymph nodes after neoadjuvant systemic treatment in patients with initially Node-Positive breast cancer correlates with disease free survival: an exploratory analysis of the GeparOcto trial. *Cancers (Basel)* 2022;14(3).
- [49] Masuda N, Lee SJ, Ohtani S, Im YH, Lee ES, Yokota I, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. *N Engl J Med* 2017;376(22):2147–59.
- [50] Geyer Jr CE, Untch M, Huang CS, Mano MS, Mamounas EP, Wolmark N, et al. Survival with trastuzumab emtansine in residual HER2-Positive breast cancer. *N Engl J Med* 2025;392(3):249–57.
- [51] Geyer Jr CE, Garber JE, Gelber RD, Yothers G, Taboada M, Ross L, et al. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. *Ann Oncol* 2022;33(12):1250–68.
- [52] Barron AU, Hoskin TL, Day CN, Hwang ES, Kuerer HM, Boughey JC. Association of low nodal positivity rate among patients with ERBB2-Positive or triple-negative breast cancer and breast pathologic complete response to neoadjuvant chemotherapy. *JAMA Surg* 2018;153(12):1120–6.
- [53] Reimer T, Glass A, Botteri E, Loibl S, O DG. Avoiding axillary sentinel lymph node biopsy after neoadjuvant systemic therapy in breast cancer: rationale for the prospective, multicentric EUBREAST-01 trial. *Cancers (Basel)* 2020;12(12).
- [54] Kuehn T, Bauerfeind I, Fehm T, Fleige B, Hausschild M, Helms G, et al. Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. *Lancet Oncol* 2013;14(7):609–18.
- [55] Kuhn T, Banys-Paluchowski M, Ditsch N, Stickeler E, Hauptmann M, Schroth J, et al. More versus less invasive axillary surgical staging procedures in breast cancer patients converting from a clinically node-positive to a clinically node-negative stage through neoadjuvant chemotherapy - primary endpoint analysis of the international prospective multicenter AXSANA/EUBREAST 3(R) study. *San Antonio Breast Cancer Symposium 2025; GS-02*. 2025.
- [56] Banys-Paluchowski M, Gasparri ML, de Boniface J, Gentilini O, Stickeler E, Hartmann S, et al. Surgical management of the axilla in clinically node-positive breast cancer patients converting to clinical node negativity through neoadjuvant chemotherapy: current status, knowledge gaps, and rationale for the EUBREAST-03 AXSANA study. *Cancers (Basel)* 2021;13(7).
- [57] Montagna G, Mrdutt MM, Sun SX, Hlavin C, Diego EJ, Wong SM, et al. Omission of axillary dissection following nodal downstaging with neoadjuvant chemotherapy. *JAMA Oncol* 2024;10(6):793–8.
- [58] Kahler-Ribeiro-Fontana S, Pagan E, Magnoni F, Vicini E, Morigi C, Corso G, et al. Long-term standard sentinel node biopsy after neoadjuvant treatment in breast cancer: a single institution ten-year follow-up. *Eur J Surg Oncol* 2020.
- [59] Cabioglu N, Kocer HB, Karanlik H, Gulcelik MA, Igci A, Muslumanoglu M, et al. De-Escalation of nodal surgery in clinically node-positive breast cancer. *JAMA Surg* 2025;160(3):257–66.
- [60] Kuemmel S, Heil J, Rueland A, Seiberling C, Harrach H, Schindowski D, et al. A prospective, multicenter registry study to evaluate the clinical feasibility of targeted axillary dissection (TAD) in node-Positive breast cancer patients. *Ann Surg* 2022;276(5):e553–62.
- [61] Montagna G, Mrdutt MM, Botto A, Barrio AV, Sevilimedu V, Boughey JC, et al. Abstract GS4-02: oncological outcomes following omission of axillary lymph node dissection in node positive patients downstaging to node negative with neoadjuvant chemotherapy. *Cancer Res* 2023;83. GS4-02-GS04-02.
- [62] Weber WP, Davide Gentilini O, Morrow M, Montagna G, de Boniface J, Fitzal F, et al. Uncertainties and controversies in axillary management of patients with breast cancer. *Cancer Treat Rev* 2023;117:102556.
- [63] Loveland-Jones C, Gaughan J, Caudle A, Murphy B, Samiian L, Byrum S, et al. Evaluation of traditional targeted axillary dissection eligibility criteria for node-positive breast cancer after neoadjuvant chemotherapy in a prospective multicenter registry. *Eur J Surg Oncol* 2024;50(4):108245.
- [64] Banys-Paluchowski M, Hartmann S, de Boniface J, Gentilini OD, Ditsch N, Stickeler E, et al. Marking techniques for target lymph nodes in node-positive breast cancer treated with neoadjuvant therapy in the AXSANA/EUBREAST-03/AGO-B-053 study. *J Clin Oncol* 2026;44(7):575–85.
- [65] Hartmann S, Banys-Paluchowski M, Berger T, Ditsch N, Stickeler E, de Boniface J, et al. Consequences of lost axillary markers after neoadjuvant chemotherapy in breast cancer patients - data from the prospective international AXSANA (EUBREAST 3) cohort study (NCT04373655). *Eur J Surg Oncol* 2025.
- [66] Banys-Paluchowski M, Hartmann S, Basali T, Gasparri ML, de Boniface J, Gentilini OD, et al. Radar reflectors for marking of target lymph nodes in initially node-positive patients receiving neoadjuvant chemotherapy for breast cancer-a subgroup analysis of the prospective AXSANA (EUBREAST-03) trial. *Breast Cancer Res Treat* 2025;211(1):203–11.
- [67] Gasparri ML, de Boniface J, Poortmans P, Gentilini OD, Kaidar-Person O, Banys-Paluchowski M, et al. Axillary surgery after neoadjuvant therapy in initially node-positive breast cancer: international EUBREAST survey. *Br J Surg* 2022;109(9):857–63.
- [68] Hartmann S, Banys-Paluchowski M, Stickeler E, de Boniface J, Gentilini OD, Kontos M, et al. Applicability of magnetic seeds for target lymph node biopsy after neoadjuvant chemotherapy in initially node-positive breast cancer patients: data from the AXSANA study. *Breast Cancer Res Treat* 2023;202(3):497–504.
- [69] Hartmann S, Kühn T, Hauptmann M, Stickeler E, Thill M, Fröhlich S, et al. Axillastaging nach neoadjuvanter Chemotherapie bei initial nodal-positivem Mammakarzinom in Deutschland: Erste Daten aus der AXSANA-Studie. *GebFra*; 2022.
- [70] Hartmann S, Kuhn T, Hauptmann M, Stickeler E, Thill M, Lux MP, et al. Axillary staging after neoadjuvant chemotherapy for initially node-positive breast carcinoma in Germany: initial data from the AXSANA study. *Geburtshilfe Frauenheilkd* 2022;82(9):932–40.
- [71] Di Micco R, Hartmann S, Banys-Paluchowski M, de Boniface J, Schmidt E, Ditsch N, et al. Diagnostic performance of axillary ultrasound after neoadjuvant chemotherapy in initially node-positive breast cancer patients - results from the prospective AXSANA registry trial. *Eur J Cancer* 2025;226:115607.
- [72] Kuhn T, Banys-Paluchowski M, Ditsch N, Stickeler E, Hauptmann M, Schroth J, et al. Axillary dissection for low-volume nodal involvement after neoadjuvant therapy in breast cancer: Multicentre AXSANA cohort study. *Br J Surg* 2025;112(9).
- [73] Montagna G, Alvarado M, Myers S, Mrdutt MM, Sun SX, Sevilimedu V, et al. Oncological outcomes with and without axillary lymph node dissection in patients with residual micrometastases after neoadjuvant chemotherapy (OPBC-07/microNAC): an international, retrospective cohort study. *Lancet Oncol* 2026;27(1):57–67.
- [74] Limberg JN, Jones T, Thomas SM, Ntowe KW, Dalton JC, van den Bruele AB, et al. Omission of axillary lymph node dissection in patients with residual nodal disease after neoadjuvant chemotherapy. *Ann Surg Oncol* 2024;31(13):8813–20.
- [75] Montagna G, Laws A, Ferrucci M, Mrdutt MM, Sun SX, Bademler S, et al. Nodal burden and oncologic outcomes in patients with residual isolated tumor cells after neoadjuvant chemotherapy (ypN0i+): the OPBC-05/ICARO study. *J Clin Oncol* 2025;43(7):810–20.
- [76] Gulcelik MA, Dogan L, Karanlik H, Akinci M, Ugurlu MU, Gulluoglu BM. Profile of surgical complications and complication-led reoperation rates in breast cancer patients who underwent oncoplastic breast surgery with volume displacements. *Eur J Surg Oncol* 2025;51(8):110252.
- [77] Mansell J, Weiler-Mithoff E, Stallard S, Doughty JC, Mallon E, Romics L. Oncoplastic breast conservation surgery is oncologically safe when compared to wide local excision and mastectomy. *Breast* 2017;32:179–85.
- [78] Wijman DJ, Ten Wolde B, van Groesen NR, Keemers-Gels ME, van den Wildenberg FJ, Strobbe LJ. Short term safety of oncoplastic breast conserving surgery for larger tumors. *Eur J Surg Oncol* 2017;43(4):665–71.
- [79] Kosasih S, Tayeh S, Mokbel K, Kasem A. Is oncoplastic breast conserving surgery oncologically safe? A meta-analysis of 18,103 patients. *Am J Surg* 2020;220(2):385–92.
- [80] Boughey JC, Rosenkranz KM, Ballman KV, McCall L, Haffty BG, Cuttino LW, et al. Local recurrence after breast-conserving therapy in patients with multiple ipsilateral breast cancer: results from ACOSOG Z11102 (Alliance). *J Clin Oncol* 2023. JCO2202553.
- [81] De Lorenzi F, Borelli F, Pagan E, Bagnardi V, Peradze N, Jereczek-Fossa BA, et al. Oncoplastic breast-conserving surgery for synchronous multicentric and multifocal tumors: is it oncologically safe? A retrospective matched-cohort analysis. *Ann Surg Oncol* 2022;29(1):427–36.
- [82] Pappas G, Karantanis W, Ayeni FE, Edirimanne S. Does prior breast irradiation increase complications of subsequent reduction surgery in breast cancer patients? A systematic review and meta-analysis. *Aesthetic Plast Surg* 2024;48(21):4365–80.

- [83] Nava CM, Zinner G, Martineau J, Oranges CM. Chest wall perforator flaps in partial breast reconstruction: a systematic review and meta-analysis. *Plastic Reconstr Surg, Glob Open* 2025;13(8):e6996.
- [84] Bhaskara M, Hulsman L, Ahmed S, Sidhu AS, Fathauer C, Rinne E, et al. Evaluation of aesthetic flat closure: a scoping review. *JPRAS Open* 2025;46: 69–82.
- [85] Snee IA, Rohrich RN, Bekeny JC, Lin RP, Ferdousian S, Jabbour S, et al. Aesthetic flat closure following mastectomy: a systematic review of techniques, outcomes, and patient perspectives. *Aesthetic Plast Surg* 2025.
- [86] Kaidar-Person O, Poortmans P, Offersen BV, Meattini I, Tramm T, Steyerova P, et al. Optimising mastectomy with a focus on skin and nipple-sparing approaches: a multidisciplinary point of view. *Eur J Surg Oncol* 2025;51(10):110310.
- [87] Ditsch N, Aktas B, Banys-Paluchowski M, Speiser D, Golas MM, Fasching PA. Preventive measures for patients with an elevated genetic risk for gynecological malignancies, in particular familial breast and ovarian cancer. *Dtsch Arztebl Int* 2025;122(23):648–54.
- [88] Klifto KM, Rydz AC, Biswas S, Hultman CS, Erdmann D, Phillips BT. Evidence-based medicine: systemic perioperative antibiotic prophylaxis for prevention of surgical-site infections in plastic and reconstructive surgery. *Plast Reconstr Surg* 2023;152(6):1154e–82e.
- [89] Hinson C, Sink M, Sammer D, Zhang AY, Odobescu A. Extended antibiotic prophylaxis in implant-based breast reconstruction: a systematic review and meta-analysis. *Aesthetic Surg J* 2025;45(11):1152–8.
- [90] Gahn J, Ljung Konstantinidou A, Lagergren J, Sandelin K, Glimaker M, Johansson H, et al. Effectiveness of single vs multiple doses of prophylactic intravenous antibiotics in implant-based breast reconstruction: a randomized clinical trial. *JAMA Netw Open* 2022;5(9):e2231583.
- [91] Hsieh HH, Liu PH, Chang CJ, Kuo YL, Chang TY. Effectiveness of extended antibiotic prophylaxis in implant-based breast reconstruction surgery: a meta-analysis. *J Plast Reconstr Aesthetic Surg* 2024;95:368–76.
- [92] Moyer HR, Sisson KM. The effect of early cultures and dual-port expanders on two-stage, prepectoral breast reconstruction: the 25/25 study. *Plastic Reconstr Surg, Glob Open* 2024;12(1):e5507.
- [93] Huynh MNQ, Wong CR, McRae MC, Voineskos S, McRae MH. The effects of tranexamic acid in breast surgery: a systematic review and meta-analysis. *Plast Reconstr Surg* 2023;152(6):993e–1004e.
- [94] Liechti R, van de Wall BJM, Hug U, Fritsche E, Franchi A. Tranexamic acid use in breast surgery: a systematic review and meta-analysis. *Plast Reconstr Surg* 2023; 151(5):949–57.
- [95] Fung E, Godek M, Roth JM, Montalmant KE, Yu BZ, Henderson PW. The current state of tranexamic acid in mastectomy and breast reconstruction: a systematic review and meta-analysis. *J Plast Reconstr Aesthetic Surg* 2025;104:259–72.
- [96] Fung E, Montalmant KE, Roth JM, Godek M, Li JH, Yu BZ, et al. Utility of tranexamic acid in reduction mammoplasty: a systematic review and meta-analysis. *Aesthetic Plast Surg* 2025;49(21):6055–65.
- [97] Alnajjar JS, Bakheet HA, Addas MAM, Alghamdi RA, AlSharit MA, Farghal NN, et al. Does the use of perioperative corticosteroids reduce the incidence of seroma formation after breast cancer surgery? A systematic review and meta-analysis. *Ann Saudi Med* 2025;45(6):435–44.
- [98] Clark RC, Reese MD, Attalla P, Camacho JM, Hirpara MM, Delong MR, et al. A systematic review and meta-analysis of synthetic mesh outcomes in alloplastic breast reconstruction. *Aesthet Surg J Open Forum* 2024;6. ojae066.
- [99] Arnautovic A, Williams S, Ash M, Menon A, Shauly O, Losken A. Outcomes in implant-based breast reconstruction utilizing biosynthetic mesh: a meta-analysis. *Aesthetic Surg J* 2025.
- [100] Zhang T, Ye J, Tian T. Implant based breast reconstruction using a titanium-coated polypropylene mesh (TiLOOP(R) bra): a systematic review and meta-analysis. *Aesthetic Plast Surg* 2024;48(5):925–35.
- [101] Ryu JM, Mok CW, Toesca A, Lai HW, Kuo WL, Cheng FT, et al. Consensus statement on robotic nipple sparing mastectomy expert panel. *J Breast Cancer* 2025;28(3):180–92.
- [102] Chun L, Fu Z, Zheng Y, Lin H, Hu Y, Li D. The impact of indocyanine green fluorescence imaging on skin flap necrosis: a systematic review and meta-analysis. *BMC Surg* 2025;25(1):311.
- [103] Wang P, Gu L, Qin Z, Wang Q, Ma J. Efficacy and safety of topical nitroglycerin in the prevention of mastectomy flap necrosis: a systematic review and meta-analysis. *Sci Rep* 2020;10(1):6753.
- [104] Chicco M, Huang TC, Cheng HT. Negative-pressure wound therapy in the prevention and management of complications from prosthetic breast reconstruction: a systematic review and meta-analysis. *Ann Plast Surg* 2021;87(4):478–83.
- [105] Cagney D, Simmons L, O'Leary DP, Corrigan M, Kelly L, O'Sullivan MJ, et al. The efficacy of prophylactic negative pressure wound therapy for closed incisions in breast surgery: a systematic review and meta-analysis. *World J Surg* 2020;44(5): 1526–37.
- [106] Kuruvilla AS, Yan Y, Rathi S, Wang F, Weichman KE, Ricci JA. Oncologic safety in autologous fat grafting after breast conservation therapy: a systematic review and meta-analysis of the literature. *Ann Plast Surg* 2023;90(1):106–10.
- [107] Borrelli MR, Spake CSL, Rao V, Sinha V, Crozier JW, Basta MN, et al. A systematic review and meta-analysis comparing the clinical outcomes of profunda artery perforator versus gracilis thigh flap as a second choice for autologous breast reconstruction. *Ann Plast Surg* 2023;90(5S Suppl 3):S256–67.
- [108] Zhu L, Liu C. Clinical outcomes following profunda artery perforator flap breast reconstruction: a systematic review and meta-analysis. *Aesthetic Plast Surg* 2025; 49(5):1349–68.
- [109] Troia T, Saab D, Haddock N. Profunda artery perforator characteristics and outcomes: a systematic review. *Gland Surg* 2025;14(11):2346–60.